Search

Displaying results 5341 - 5350 of 10000 in total
  1. Drug

    Field mushroom

    go.drugbank.com/drugs/DB15605
    Approved

    Field mushroom allergenic extract is used in allergenic testing.

  2. Drug

    NN-8828

    go.drugbank.com/drugs/DB18361
    Investigational

    NN-8828 is an anti-interleukin 21 monoclonal antibody.

  3. Drug

    Moricizine

    go.drugbank.com/drugs/DB00680
    ApprovedWithdrawn

    An antiarrhythmia agent used primarily for ventricular rhythm disturbances.

    Synonyms: ethyl 10-(β-N-morpholinylpropionyl)phenothiazine-2-carbamate
  4. Drug

    Branaplam

    go.drugbank.com/drugs/DB14918
    Investigational

    Branaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)).

  5. Drug

    Firtecan pegol

    go.drugbank.com/drugs/DB14953
    Investigational

    Firtecan pegol is under investigation in clinical trial NCT01036113 (A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer).

  6. Drug

    ANA975

    go.drugbank.com/drugs/DB06490
    Experimental

    ANA975 is a toll-like receptor 7 agonist that is developed for the treatment of hepatitis C.

    Synonyms: AN 975
  7. Drug

    Caldaret

    go.drugbank.com/drugs/DB06231
    Investigational

  8. Drug

    Hypothiocyanite ion

    go.drugbank.com/drugs/DB15309
    Investigational

    Hypothiocyanite ion is under investigation in clinical trial NCT02598999 (Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients).

  9. Drug

    Trelagliptin

    go.drugbank.com/drugs/DB15323
    Investigational

    Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus").

  10. Drug

    LSZ-102

    go.drugbank.com/drugs/DB15362
    Investigational

    LSZ-102 is under investigation in clinical trial NCT02734615 (Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers).